CARNITOR (levocarnitine) by Leadiant Biosciences is clinical pharmacology carnitor (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. First approved in 1992.
Drug data last refreshed 3h ago · AI intelligence enriched 3d ago
CARNITOR (levocarnitine) is a naturally occurring carnitine analog that facilitates long-chain fatty acid entry into cellular mitochondria for energy production. It is indicated for primary and secondary carnitine deficiency, including ESRD patients on hemodialysis and those with inborn errors of metabolism such as glutaric aciduria II and propionic acidemia. The drug works by clearing toxic acylCoA compounds through formation of acylcarnitine, which is rapidly excreted, thereby reducing metabolic autointoxication.
Product is in late-stage lifecycle with LOE approaching; expect consolidation of brand team and focus on managed care and retention strategies.
CLINICAL PHARMACOLOGY CARNITOR (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids…
Worked on CARNITOR at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Carnitine Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCARNITOR represents a career opportunity in specialty/rare disease management and dialysis center relationships rather than high-volume primary care. Working on this product emphasizes relationship management, reimbursement expertise, and niche market penetration in a mature, declining lifecycle stage.